Top

Published in:

01-02-2012 | Research Article

Overexpression of G6PD is associated with poor clinical outcome in gastric cancer

Authors: Jixu Wang, Weijie Yuan, Zhikang Chen, Shaobin Wu, Jinxiang Chen, Jie Ge, Futao Hou, Zihua Chen

Published in: Tumor Biology | Issue 1/2012

Abstract

This study aims to investigate the expression and significance of glucose-6-phosphate dehydrogenase (G6PD) in human gastric cancer progression and prognosis. Using immunohistochemistry and real-time RT-PCR assay, we identified abnormally elevated expression of G6PD in gastric cancer tissues compared to paired normal stomach mucosa tissues in 24 patients (p < 0.05). In order to investigate the correlations between G6PD and the clinicopathological features of gastric cancer, the expression of G6PD in 167 patients with gastric cancer were detected by immunohistochemistry, and the results showed that overexpression of G6PD was associated with the size of tumor (p = 0.039), depth of invasion (p = 0.039), lymph node metastasis (p = 0.044), distant metastasis (p = 0.003), TNM stage (p = 0.030), and survival rate (p = 0.010). Further, Cox multivariates analysis indicated that G6PD expression level was an independent prognostic factor for patients after radical resection (p = 0.013). In conclusion, overexpression of G6PD is closely related to progression of gastric cancer, and might be regarded as an independent predictor of poor prognosis for gastric cancer.

Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.

Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol. 2009;71(2):127–64.PubMedCrossRef

Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.PubMedCrossRef

Ho HY, Cheng ML, Chiu DT. Glucose-6-phosphate dehydrogenase—from oxidative stress to cellular functions and degenerative diseases. Redox Rep. 2007;12:109–18.PubMedCrossRef

Kuo W, Lin J, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3 T3 cells and induces tumors in nude mice. Int J Cancer. 2000;85:857–64.PubMedCrossRef

Batetta B, Bonatesta RR, Sanna F, Putzolu M, Mulas MF, Collu M, et al. Cell growth and cholesterol metabolism in human glucose-6-phosphate dehydrogenase deficient lymphomononuclear cells. Cell Prolif. 2002;35:143–54.PubMedCrossRef

Li D, Zhu Y, Tang Q, Huiru Lu, Li H, Yang Y, et al. A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. Cancer Biother Radiopharm. 2009;24:81–90.PubMedCrossRef

Ohl F, Jung M, Radonić A, Sachs M, Loening SA, Jung K. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol. 2006;175:1915–20.PubMedCrossRef

Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, et al. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer. 2008;122:2422–8.PubMedCrossRef

10.

Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, et al. Cellular gluathione content in vitro chemo response and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol Oncol. 2002;85:298.PubMedCrossRef

11.

Frederiks WM, van Marle J, van Oven C, Comin-Anduix B, Cascante M. Improved localization of glucose-6-phosphate dehydrogenase activity in cells with 5-cyano-2, 3-ditolyl-tetrazolium chloride as fluorescent redox dye reveals its cell cycle-dependent regulation. J Histochem Cytochem. 2006;54:47–52.PubMedCrossRef

12.

Bokun R, Bakotin J, Milasinovic DD. Semiquantitative cytochemical estimation of glucose-6-phosphate dehydrogenase activity in benign diseases and carcinoma of the breast. Acta Cytol. 1987;31:249–52.PubMed

13.

Hughes EC. The effect of enzymes upon metabolism, storage, and release of carbohydrates in normal and abnormal endometria. Cancer. 1976;38:487–502.PubMedCrossRef

14.

Dutu R, Nedelea M, Veluda G, Burcuket V. Cytoenzymologic investigations on carcinomas of the cervix uteri. Acta Cytol. 1980;24:160–6.PubMed

15.

Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med. 2005;83:1014–24.PubMedCrossRef

16.

Zampella EJ, Bradley EL, Pretlow IG. Glucose-6-phosphate dehydrogenase: a possible clinical indicator for prostatic carcinoma. Cancer. 1982;49:384–7.PubMedCrossRef

17.

Dessi S, Batetta B, Cherchi R, Onnis R, Pisano M, Pani P. Hexomonophosphate shunt enzymes in lung tumours from normal and glucose-6-phosphate dehydrogenase-deficient subjects. Oncology. 1988;45:287–91.PubMedCrossRef

18.

Li R, Jiang C. Expression of G6PD protein in gliomas and its correlation with glioma grades. Heilongjiang Med J. 2008;32:573–5.

19.

Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.

20.

Kekec Y, Paydas S, Tuli A, Zorludemir S, Sakman G, Seydaoglu G. Antioxidant enzyme levels in cases with gastrointestinal cancer. Eur J Intern Med. 2009;20(4):403–6.PubMedCrossRef

21.

Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to acritical role for type II hexokinase. J Bioenerg Biomembr. 1997;29:339–43.PubMedCrossRef

22.

Vizán P, Alcarraz-Vizán G, Díaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer. 2009;124:2789–96.PubMedCrossRef

23.

Chen H, Yue JX, Yang SH, Ding H, Zhao RW, Zhang S. Over expression of transketolase-like gene1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009;28:43.PubMedCrossRef

24.

Dessì S, Batetta B, Pani P, Barra S, Miranda F, Puxeddu P. Glucose-6-phosphate dehydrogenase (G6PD) activity in tumoral tissues of GGPD-deficient subjects affected by larynx carcinoma. Cancer Lett. 1990;53:159–62.PubMedCrossRef

25.

Yuan W, Shaobin Wu, Guo J, Chen Z, Jie Ge Pu, Yang Bin Hu, et al. Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010;9(9):710–6.PubMedCrossRef

26.

Tian Wang-Ni, Braunstein LD, Pang J, Stuhlmeier KM, Xi Q-C, Tian X, et al. Stanton. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem. 1998;273:10609–17.PubMedCrossRef

27.

Forteleoni G, Argiolas L, Farris A, Ferraris AM, Gaetani GF, Meloni T. G6PD deficiency and breast cancer. Tumori. 1988;74:665–7.PubMed

28.

Pisano M, Cocco P, Cherchi R, Onnis R, Cherchi P. Glucose-6-phosphate dehydrogenase deficiency and lung cancer: a hospital based case-control study. Tumori. 1991;77:12–5.PubMed

29.

Tassi S, Carta S, Delfino L, Caorsi R, Martini A, Gattorno M, et al. Altered redox state of monocytes from cryopyrinassociated periodic syndromes causes accelerated IL-1β secretion. Proc Natl Acad Sci USA. 2010;107(21):9789–94.PubMedCrossRef

30.

Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, et al. Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes. 2006;55(11):2939–49.PubMedCrossRef

31.

Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.PubMedCrossRef

32.

Wells PG, Bhuller Y, Chen CS, Jeng W, Kasapinovic S, Kennedy JC, et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol Appl Pharmacol. 2005;207:354–66.PubMedCrossRef

33.

Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, et al. Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity. Biochem J. 2011;439(1):141–9.PubMedCrossRef

Title: Overexpression of G6PD is associated with poor clinical outcome in gastric cancer
Authors: Jixu Wang
Weijie Yuan
Zhikang Chen
Shaobin Wu
Jinxiang Chen
Jie Ge
Futao Hou
Zihua Chen
Publication date: 01-02-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-011-0251-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population

Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity

Metabolic restriction of cancer cells in vitro causes karyotype contraction—an indicator of cancer promotion?

Podoplanin expression during dysplasia–carcinoma sequence in the oral cavity

COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line

Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses

Keynote webinar | Spotlight on antibody–drug conjugates in cancer